• Latest Posts
Sponsored by 10 Oct 2023

Drugging ‘undruggable’ targets: Are high-throughput proximity assays the answer?

AAVantgarde closes €61M financing to move gene delivery program to the clinic

Italian life sciences fund hits €175M

Newron reports ‘striking’ schizophrenia study results 

ADVERTISEMENT

Orbsen Therapeutics happy with interim diabetic kidney disease study results 

Beyond Biotech podcast 28: Mainz Biomed, Newron Pharmaceuticals

Newron announces interim results from treatment-resistant schizophrenia trial

Watch: Interview with IRBM’s Heidi Kingdon Jones

Interview 14 Dec 2022

Sibylla Biotech: how physicists met biologists to discover new drugs

Partnership to deliver oncology workflow for 7 European hospitals

ADVERTISEMENT